Login to Your Account

Regulatory NEWS

As the realities of building a million-person research group for the federal Precision Medicine Initiative come into clearer focus, the thorny issues of data privacy, security and control moved to the fore during the second day of a National Institutes of Health-sponsored workshop on participant engagement and health equity.

BOGOTA, Colombia – Brazil's health surveillance agency, Anvisa, approved the commercialization of Sylvant (siltuximab) to treat patients with multicentric Castleman's disease (MCD) who do not have HIV and the human herpesvirus-8 infection. The application was filed by Sao Paulo-based Janssen-Cilag Farmacêutica, a subsidiary of Belgium's Janssen Pharmaceutical, which in turn is owned by Johnson & Johnson, of New Brunswick, N.J.

In a bit of regulatory house cleaning, the FDA is tossing a few obsolete or duplicative rules for certain biologics-makers and reducing the need for animal testing.

More Regulatory Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: